Sol Gel Technologies Ltd
NASDAQ:SLGL
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
SLGL's latest stock split occurred on May 5, 2025
The company executed a 1-for-10 stock split, meaning that for every 10 shares held, investors received 1 new share.
Before the split, SLGL traded at 0.73 per share. Afterward, the share price was about 4.42.
The adjusted shares began trading on May 5, 2025. This was the only stock split in SLGL's history.
Global
Stock Splits Monitor
| Date | Company | Split | Pre-Split Price | Post-Split Price | |
|---|---|---|---|---|---|
|
Apr 21, 2026
|
W
|
WellCell Holdings Co Ltd
HKEX:2477
|
4-for-1
x4
|
111.28 111.28 HKD | N/A |
|
Apr 21, 2026
|
|
Canon Electronics Inc
TSE:7739
|
1-for-6235122
/6235122
|
3635 3635 JPY | N/A |
|
Apr 20, 2026
|
|
AnaptysBio Inc
NASDAQ:ANAB
|
15-for-10
x1.5
|
67.5101 45.0067 USD | 50.95 50.95 USD |
|
Apr 20, 2026
|
|
ConnectM Technology Solutions Inc
NASDAQ:CNTM
|
1-for-32
/32
|
0.265 8.48 USD | 8.48 8.48 USD |
|
Apr 20, 2026
|
M
|
Mdundocom A/S
CSE:MDUNDO
|
10-for-9
x1.1111111111111
|
1.25 1.125 DKK | 1.03 1.03 DKK |
7739
ANAB
CNTM
Sol Gel Technologies Ltd
Glance View
Sol-Gel Technologies Ltd. is a clinical-stage dermatology company, which engages in the identification, development, and commercialization of topical dermatological drug products for the treatment of skin diseases. The firm is focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The Company’s offers a range of products twins, sirs-t, and vered. The firm is designed its proprietary, silica-based microencapsulation technology platform to enhance the tolerability and stability of topical drugs while maintaining their efficacy. Topical drugs often struggle to balance achieving both high efficacy and high tolerability. Its technology platform entraps active ingredients in an inert, inorganic silica shell, which creates an unnoticeable barrier between the active ingredient and the skin.
